Free Trial

Healthcare and Medical Stocks List

This page shows information about the 50 largest healthcare and medical sector stocks including Eli Lilly and Company, Johnson & Johnson, AbbVie and Novartis. Learn more about health care stocks.

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$746.17 -19.78 (-2.58%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$753.75 +7.58 (+1.02%)
As of 08/6/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • The current stock price is around $761, reflecting strong market interest and potential for growth.
  • Seventeen analysts have issued a buy rating, indicating strong confidence in the company's future performance.
  • The company reported a significant year-over-year revenue increase of over 45%, showcasing robust business growth.

Cons of Eli Lilly and Company

  • The company recently missed earnings expectations, reporting $3.34 EPS compared to the consensus estimate of $4.64, which may raise concerns about future profitability.
  • One analyst has rated the stock with a sell rating, indicating potential risks that could affect stock performance.
  • HSBC downgraded the stock from a buy to a reduce rating, reflecting a more cautious outlook from some market experts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$725.92 billion
P/E Ratio
60.71
Consensus Rating
Moderate Buy
Consensus Price Target
$1,012.56 (+35.7% Upside)
Volume
4.72 million shares
Average Volume
3.58 million shares
Today's Range
$740.19
$763.00
50-Day Range
$720.91
$818.56
52-Week Range
$677.09
$972.53
Dividend Yield
0.78%
Johnson & Johnson stock logo

2. Johnson & Johnson NYSE:JNJ

$170.72 -0.02 (-0.01%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$170.86 +0.15 (+0.09%)
As of 08/6/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • The current stock price is around $167, reflecting a stable performance in the market.
  • Johnson & Johnson recently reported earnings per share (EPS) of $2.77, exceeding analyst expectations, which indicates strong financial health and operational efficiency.
  • The company has a solid revenue growth of 5.8% year-over-year, showcasing its ability to expand and adapt in a competitive market.

Cons of Johnson & Johnson

  • Despite recent earnings growth, the company reported a slight decline in EPS compared to the previous year, which may raise concerns about future profitability.
  • Johnson & Johnson has a relatively high price-to-earnings (P/E) ratio of 17.90, which could suggest that the stock is overvalued compared to its earnings potential.
  • The company has a debt-to-equity ratio of 0.50, indicating a moderate level of debt that could impact financial flexibility in challenging economic conditions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$411.20 billion
P/E Ratio
18.26
Consensus Rating
Moderate Buy
Consensus Price Target
$174.50 (+2.2% Upside)
Volume
8.96 million shares
Average Volume
9.23 million shares
Today's Range
$169.68
$172.18
50-Day Range
$149.81
$171.08
52-Week Range
$140.68
$172.18
Dividend Yield
3.05%
AbbVie stock logo

3. AbbVie NYSE:ABBV

$196.37 -2.18 (-1.10%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$196.45 +0.08 (+0.04%)
As of 08/6/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • The current stock price is around $195, reflecting a strong market presence and investor interest.
  • AbbVie reported a revenue increase of 6.6% year-over-year, indicating robust growth in its business operations.
  • The company has a high return on equity, showcasing its efficiency in generating profits from shareholders' equity.

Cons of AbbVie

  • The stock has a high price-to-earnings ratio, which may indicate that it is overvalued compared to its earnings potential.
  • AbbVie recently missed earnings estimates, which could raise concerns about its ability to meet future financial expectations.
  • The company has a significant debt-to-equity ratio, suggesting a reliance on debt financing that could pose risks in a rising interest rate environment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$350.75 billion
P/E Ratio
93.51
Consensus Rating
Moderate Buy
Consensus Price Target
$212.81 (+8.4% Upside)
Volume
4.06 million shares
Average Volume
5.36 million shares
Today's Range
$194.67
$198.05
50-Day Range
$181.89
$198.53
52-Week Range
$163.81
$218.66
Dividend Yield
3.30%
Novartis stock logo

4. Novartis NYSE:NVS

$113.55 -4.18 (-3.55%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$113.28 -0.27 (-0.23%)
As of 08/6/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • The current stock price is around $117, reflecting a recent increase, which may indicate positive market sentiment towards the company.
  • Novartis AG reported strong earnings, exceeding analysts' expectations, with a quarterly revenue increase of over 12% year-over-year, showcasing robust business performance.
  • The company has a solid market capitalization of approximately $247 billion, indicating its stability and potential for growth in the pharmaceutical sector.

Cons of Novartis

  • Despite recent upgrades, there are still analysts who have rated the stock with a "sell" or "hold" rating, indicating mixed sentiments about its future performance.
  • The company has seen significant selling from institutional investors, with some reducing their stakes by over 90%, which may raise concerns about insider confidence.
  • Novartis AG has a relatively high P/E ratio compared to industry averages, which could suggest that the stock is overvalued at its current price.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$248.70 billion
P/E Ratio
16.53
Consensus Rating
Hold
Consensus Price Target
$123.67 (+8.9% Upside)
Volume
2.02 million shares
Average Volume
2.12 million shares
Today's Range
$113.48
$115.44
50-Day Range
$111.88
$123.83
52-Week Range
$96.06
$124.83
Dividend Yield
2.20%
AstraZeneca stock logo

5. AstraZeneca NASDAQ:AZN

$73.60 -0.88 (-1.18%)
Closing price 08/6/2025 04:00 PM Eastern
Extended Trading
$73.32 -0.28 (-0.38%)
As of 08/6/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. More about AstraZeneca

Pros of AstraZeneca

  • The current stock price is around $73.95, which may present a buying opportunity for investors looking for growth in the biopharmaceutical sector.
  • AstraZeneca reported a revenue increase of 16.1% compared to the same quarter last year, indicating strong business performance and potential for future growth.
  • The company has a solid return on equity of 33.14%, suggesting effective management and profitability, which can be attractive to investors.

Cons of AstraZeneca

  • The price-to-earnings ratio is currently at 30.62, which may indicate that the stock is overvalued compared to its earnings, potentially leading to a price correction.
  • The company's current ratio of 0.90 suggests that it may have difficulty meeting short-term liabilities, which could raise concerns about liquidity.
  • AstraZeneca's beta of 0.37 indicates lower volatility compared to the market, which may not appeal to investors seeking high-risk, high-reward opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$230.99 billion
P/E Ratio
27.67
Consensus Rating
Moderate Buy
Consensus Price Target
$89.00 (+20.9% Upside)
Volume
2.95 million shares
Average Volume
5.41 million shares
Today's Range
$73.42
$75.10
50-Day Range
$68.72
$76.59
52-Week Range
$61.24
$87.68
Dividend Yield
2.77%
UnitedHealth Group stock logo

6. UnitedHealth Group NYSE:UNH

$245.59 -5.41 (-2.16%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$245.70 +0.11 (+0.04%)
As of 08/6/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. More about UnitedHealth Group

Pros of UnitedHealth Group

  • The current stock price is around $373.52, which reflects a consensus rating of "Hold" from analysts, indicating potential stability in the stock's performance.
  • UnitedHealth Group has received multiple "buy" ratings from analysts, suggesting strong confidence in the company's growth prospects and market position.
  • Recent insider buying activity, including a significant purchase by the CFO, indicates that company leadership is optimistic about the future performance of the stock.

Cons of UnitedHealth Group

  • Some analysts have downgraded their ratings, with a few moving from "buy" to "hold," which may indicate concerns about the company's short-term performance.
  • There are several "sell" ratings from analysts, suggesting that a portion of the market may have reservations about the company's future growth.
  • Recent price target reductions by analysts could signal a lack of confidence in the stock's ability to maintain its previous highs.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$227.69 billion
P/E Ratio
10.64
Consensus Rating
Moderate Buy
Consensus Price Target
$366.52 (+49.2% Upside)
Volume
12.89 million shares
Average Volume
18.40 million shares
Today's Range
$245.31
$253.16
50-Day Range
$237.40
$325.83
52-Week Range
$234.60
$630.73
Dividend Yield
3.52%
Abbott Laboratories stock logo

7. Abbott Laboratories NYSE:ABT

$131.01 +0.32 (+0.25%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$131.10 +0.09 (+0.07%)
As of 08/6/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • The current stock price is around $127, reflecting a stable position in the market.
  • Abbott Laboratories reported a strong quarterly revenue of $11.14 billion, exceeding analyst expectations, indicating robust business performance.
  • The company has a high net margin of over 32%, suggesting efficient management and profitability.

Cons of Abbott Laboratories

  • Despite strong performance, the stock has seen fluctuations, with a 1-year high of $141.23 and a low of $107.11, indicating potential volatility.
  • The company's price-to-earnings ratio of 15.95 may suggest that the stock is overvalued compared to its earnings, which could deter some investors.
  • Abbott Laboratories operates in a highly competitive healthcare market, which may impact future growth and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$227.46 billion
P/E Ratio
16.42
Consensus Rating
Moderate Buy
Consensus Price Target
$144.47 (+10.3% Upside)
Volume
5.17 million shares
Average Volume
7.85 million shares
Today's Range
$129.81
$131.72
50-Day Range
$120.76
$138.13
52-Week Range
$107.11
$141.23
Dividend Yield
1.81%
Novo Nordisk A/S stock logo

8. Novo Nordisk A/S NYSE:NVO

$45.31 -1.91 (-4.04%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$45.54 +0.23 (+0.51%)
As of 08/6/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • The current stock price is around $48.87, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • Recent trading activity has shown unusually high options volume, indicating increased investor interest and potential for price movement.
  • Analysts have set an average price target of $93.67, suggesting significant upside potential from the current price.

Cons of Novo Nordisk A/S

  • Several analysts have downgraded their ratings on the stock, with some moving from "buy" to "hold," which may indicate a lack of confidence in short-term performance.
  • The stock has experienced a significant decline from its 52-week high of $139.74, raising concerns about its current valuation and market sentiment.
  • With a debt-to-equity ratio of 0.70, while manageable, it suggests that the company is somewhat reliant on debt financing, which can be risky in volatile markets.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$210.84 billion
P/E Ratio
13.41
Consensus Rating
Hold
Consensus Price Target
$93.67 (+106.7% Upside)
Volume
37.33 million shares
Average Volume
20.61 million shares
Today's Range
$45.05
$46.49
50-Day Range
$45.31
$81.07
52-Week Range
$45.05
$139.74
Dividend Yield
3.47%
Merck & Co., Inc. stock logo

9. Merck & Co., Inc. NYSE:MRK

$79.41 -1.38 (-1.71%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$79.35 -0.06 (-0.08%)
As of 08/6/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • The current stock price is around $80, which may present a buying opportunity for investors looking for value.
  • Merck has a strong market capitalization of approximately $199 billion, indicating a solid position in the pharmaceutical industry.
  • The company reported earnings per share (EPS) of $2.13, exceeding analyst expectations, which reflects strong financial performance.

Cons of Merck & Co., Inc.

  • Recent price target reductions by analysts, including a drop to $90 from $97, may indicate a lack of confidence in short-term growth.
  • Merck's revenue for the last quarter was slightly below analyst estimates, which could raise concerns about future performance.
  • The company has a debt-to-equity ratio of 0.69, which, while manageable, indicates some level of financial leverage that could pose risks.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$202.87 billion
P/E Ratio
12.24
Consensus Rating
Hold
Consensus Price Target
$107.44 (+35.3% Upside)
Volume
12.03 million shares
Average Volume
12.85 million shares
Today's Range
$79.27
$81.32
50-Day Range
$76.22
$84.82
52-Week Range
$73.31
$120.30
Dividend Yield
4.06%
Thermo Fisher Scientific stock logo

10. Thermo Fisher Scientific NYSE:TMO

$449.68 -16.74 (-3.59%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$450.56 +0.88 (+0.20%)
As of 08/6/2025 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • The company recently reported a quarterly revenue increase of 2.9% compared to the same quarter last year, indicating stable growth in its operations.
  • Thermo Fisher Scientific Inc. has a strong earnings per share (EPS) forecast of 23.28 for the current fiscal year, suggesting potential profitability and positive financial performance.
  • The current stock price is around $462.74, which may present a buying opportunity for investors looking to enter at a lower price point compared to its one-year high of $627.88.

Cons of Thermo Fisher Scientific

  • The stock has experienced a decline of about 1.1% recently, which may raise concerns about short-term performance.
  • Several analysts have adjusted their price targets downward, with notable reductions from firms like Wells Fargo and Stifel Nicolaus, indicating potential market skepticism.
  • Insider selling activity has been noted, with an executive recently selling shares, which could signal a lack of confidence in the stock's near-term prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$176.13 billion
P/E Ratio
26.01
Consensus Rating
Moderate Buy
Consensus Price Target
$593.00 (+31.9% Upside)
Volume
2.54 million shares
Average Volume
3.31 million shares
Today's Range
$446.28
$466.50
50-Day Range
$390.17
$484.90
52-Week Range
$385.46
$627.88
Dividend Yield
0.37%
Intuitive Surgical stock logo

11. Intuitive Surgical NASDAQ:ISRG

$474.06 -2.94 (-0.62%)
Closing price 08/6/2025 04:00 PM Eastern
Extended Trading
$473.86 -0.20 (-0.04%)
As of 08/6/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • The current stock price is around $585, reflecting a strong market interest and potential for growth.
  • Intuitive Surgical, Inc. reported impressive quarterly earnings, exceeding analyst expectations with a significant increase in revenue year-over-year, indicating robust business performance.
  • The company has received a majority of buy ratings from analysts, suggesting positive sentiment and confidence in its future performance.

Cons of Intuitive Surgical

  • The stock has a high price-to-earnings (P/E) ratio, which may indicate that it is overvalued compared to its earnings, posing a risk for potential investors.
  • Recent insider selling activity, with significant shares sold by executives, could signal a lack of confidence in the company's short-term prospects.
  • The stock's beta of 1.60 suggests higher volatility compared to the market, which could lead to greater risk for investors during market fluctuations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$170.99 billion
P/E Ratio
66.12
Consensus Rating
Moderate Buy
Consensus Price Target
$595.95 (+25.7% Upside)
Volume
2.19 million shares
Average Volume
2.26 million shares
Today's Range
$473.26
$480.99
50-Day Range
$474.06
$558.06
52-Week Range
$425.00
$616.00
Dividend Yield
N/A
Amgen stock logo

12. Amgen NASDAQ:AMGN

$284.67 -15.41 (-5.14%)
Closing price 08/6/2025 04:00 PM Eastern
Extended Trading
$284.25 -0.42 (-0.15%)
As of 08/6/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • The current stock price is around $300, which may present a buying opportunity for investors looking for value in the biotechnology sector.
  • Amgen Inc. has a strong dividend yield of 3.2%, providing a steady income stream for investors, which is particularly attractive in a low-interest-rate environment.
  • The company has a solid payout ratio of 86.86%, indicating that it is returning a significant portion of its earnings to shareholders while still retaining enough to invest in growth.

Cons of Amgen

  • Despite a strong dividend, the company's high payout ratio may limit its ability to reinvest in research and development, which is crucial for long-term growth in the biotech industry.
  • Recent insider selling, including a significant transaction by a senior vice president, may raise concerns about the company's future performance and insider confidence.
  • Amgen Inc. has faced mixed analyst ratings, with a significant number of hold and sell ratings, indicating uncertainty among market experts regarding its future prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$161.35 billion
P/E Ratio
23.28
Consensus Rating
Hold
Consensus Price Target
$307.23 (+7.9% Upside)
Volume
4.58 million shares
Average Volume
1.89 million shares
Today's Range
$281.65
$298.54
50-Day Range
$272.44
$309.22
52-Week Range
$253.30
$339.17
Dividend Yield
3.17%
Boston Scientific stock logo

13. Boston Scientific NYSE:BSX

$102.92 -1.91 (-1.82%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$102.60 -0.32 (-0.31%)
As of 08/6/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • The current stock price is around $105.40, reflecting a stable performance in the market.
  • Boston Scientific Co. reported a significant revenue increase of 22.8% year-over-year, indicating strong growth potential.
  • The company exceeded analysts' earnings expectations, posting $0.75 EPS compared to the consensus estimate of $0.72, showcasing effective management and operational efficiency.

Cons of Boston Scientific

  • Insider selling has been notable, with over 282,000 shares sold recently, which may indicate a lack of confidence among executives.
  • The stock has experienced fluctuations, with a 52-week high of $108.94 and a low of $71.88, suggesting volatility that could deter risk-averse investors.
  • Insiders currently own only 0.50% of the stock, which may raise concerns about alignment between management and shareholder interests.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$155.33 billion
P/E Ratio
61.26
Consensus Rating
Buy
Consensus Price Target
$117.50 (+14.2% Upside)
Volume
9.11 million shares
Average Volume
7.56 million shares
Today's Range
$101.60
$105.38
50-Day Range
$98.43
$107.51
52-Week Range
$73.61
$108.94
Dividend Yield
N/A
Stryker stock logo

14. Stryker NYSE:SYK

$374.93 -5.93 (-1.56%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$374.82 -0.11 (-0.03%)
As of 08/6/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • The current stock price is around $381, which may present a buying opportunity for investors looking for growth in the medical technology sector.
  • Stryker Co. has received multiple upgrades from analysts, with a consensus target price of approximately $430.10, indicating potential for price appreciation.
  • The company reported strong quarterly earnings, exceeding analysts' expectations with earnings per share of $3.13, showcasing its robust financial performance.

Cons of Stryker

  • The stock has a high price-to-earnings (P/E) ratio of around 50, which may suggest that it is overvalued compared to its earnings, potentially limiting future price growth.
  • Despite recent revenue growth, the company faces significant competition in the medical technology field, which could impact its market share and profitability.
  • The debt-to-equity ratio of 0.70 indicates that Stryker Co. has a moderate level of debt, which could pose risks if interest rates rise or if the company faces financial challenges.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$145.61 billion
P/E Ratio
49.66
Consensus Rating
Moderate Buy
Consensus Price Target
$430.10 (+14.7% Upside)
Volume
1.48 million shares
Average Volume
1.30 million shares
Today's Range
$374.32
$381.24
50-Day Range
$373.22
$403.34
52-Week Range
$319.07
$406.19
Dividend Yield
0.88%
Danaher stock logo

15. Danaher NYSE:DHR

$195.34 -3.70 (-1.86%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$196.18 +0.84 (+0.43%)
As of 08/6/2025 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • The current stock price is around $199, reflecting a recent increase, which may indicate positive market sentiment towards the company.
  • Danaher Co. has consistently outperformed earnings expectations, recently reporting earnings per share that exceeded analyst estimates, showcasing strong financial performance.
  • The company has a robust market capitalization of approximately $142 billion, indicating its significant presence and stability in the market.

Cons of Danaher

  • The stock has experienced volatility, with a 12-month high of $279.90 and a low of $171.00, indicating potential risks associated with price fluctuations.
  • Despite recent earnings growth, the company's price-to-earnings (PE) ratio is relatively high, which may suggest that the stock is overvalued compared to its earnings.
  • Insider selling activity has been noted, with significant shares sold by the chairman, which could raise concerns about the company's future prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$142.52 billion
P/E Ratio
41.56
Consensus Rating
Moderate Buy
Consensus Price Target
$247.61 (+26.8% Upside)
Volume
5.12 million shares
Average Volume
4.69 million shares
Today's Range
$194.15
$199.05
50-Day Range
$188.23
$206.83
52-Week Range
$171.00
$279.90
Dividend Yield
0.65%
Pfizer stock logo

16. Pfizer NYSE:PFE

$23.95 -0.80 (-3.24%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$23.99 +0.04 (+0.18%)
As of 08/6/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • The current stock price is around $24.49, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • Pfizer Inc. reported strong earnings recently, with earnings per share (EPS) of $0.78, exceeding analyst expectations, indicating robust financial performance.
  • The company has shown a year-over-year revenue increase of 10.3%, suggesting growth potential and a solid market position.

Cons of Pfizer

  • Recent downgrades from various analysts have lowered price targets, with some suggesting a more cautious outlook on the stock's performance.
  • The stock has a relatively high dividend payout ratio of 124.64%, which may raise concerns about sustainability if earnings do not continue to grow.
  • Market volatility and economic uncertainties could impact Pfizer Inc.'s stock performance, making it a riskier investment in the current climate.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$140.71 billion
P/E Ratio
12.74
Consensus Rating
Moderate Buy
Consensus Price Target
$28.44 (+18.8% Upside)
Volume
65.64 million shares
Average Volume
44.82 million shares
Today's Range
$23.86
$24.71
50-Day Range
$23.11
$25.77
52-Week Range
$20.92
$30.43
Dividend Yield
6.95%
Gilead Sciences stock logo

17. Gilead Sciences NASDAQ:GILD

$110.28 -2.18 (-1.94%)
Closing price 08/6/2025 04:00 PM Eastern
Extended Trading
$110.30 +0.02 (+0.02%)
As of 08/6/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More about Gilead Sciences

Pros of Gilead Sciences

  • The current stock price is around $113, reflecting a recent increase, which may indicate positive market sentiment towards the company.
  • Gilead Sciences, Inc. has received multiple upgrades from analysts, with recent ratings including a "buy" from Needham & Company LLC and an "overweight" from Morgan Stanley, suggesting strong future performance expectations.
  • The company has a solid market capitalization of approximately $140.79 billion, indicating its significant presence and stability in the biopharmaceutical sector.

Cons of Gilead Sciences

  • Despite recent upgrades, the consensus price target remains lower than the current stock price, which may indicate that the stock could face downward pressure in the near term.
  • Insider selling has been notable, with significant shares sold recently, which could raise concerns about the executives' confidence in the company's future performance.
  • The company has a debt-to-equity ratio of 1.16, which suggests that it has a relatively high level of debt compared to its equity, potentially increasing financial risk.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$139.89 billion
P/E Ratio
23.22
Consensus Rating
Moderate Buy
Consensus Price Target
$112.36 (+1.9% Upside)
Volume
7.44 million shares
Average Volume
5.54 million shares
Today's Range
$110.19
$112.25
50-Day Range
$105.93
$116.20
52-Week Range
$72.43
$119.96
Dividend Yield
2.76%
Sanofi stock logo

18. Sanofi NASDAQ:SNY

$46.18 -1.66 (-3.47%)
Closing price 08/6/2025 04:00 PM Eastern
Extended Trading
$46.15 -0.03 (-0.07%)
As of 08/6/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • The current stock price is around $46.75, which may present a buying opportunity for investors looking for value.
  • Sanofi reported a revenue of $11.34 billion in its latest quarter, exceeding analysts' expectations, indicating strong market performance.
  • The company has a solid market capitalization of approximately $114.80 billion, reflecting its stability and potential for growth.

Cons of Sanofi

  • The company experienced a year-over-year revenue decline of 7.0%, which may raise concerns about its growth trajectory.
  • Sanofi's earnings per share (EPS) of $0.90 missed analysts' consensus estimates, suggesting potential challenges in meeting market expectations.
  • The stock has a relatively low beta of 0.48, indicating lower volatility, which may not appeal to investors seeking high-risk, high-reward opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$117.47 billion
P/E Ratio
11.10
Consensus Rating
Buy
Consensus Price Target
$62.00 (+34.3% Upside)
Volume
3.49 million shares
Average Volume
2.30 million shares
Today's Range
$46.14
$47.47
50-Day Range
$45.64
$52.35
52-Week Range
$44.73
$60.12
Dividend Yield
3.34%
Medtronic stock logo

19. Medtronic NYSE:MDT

$89.35 -0.32 (-0.36%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$89.35 0.00 (0.00%)
As of 08/6/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • The current stock price is around $89.92, which may present a buying opportunity for investors looking for value in the medical technology sector.
  • Medtronic plc recently reported strong earnings, with an EPS of $1.62, exceeding expectations and indicating solid financial performance.
  • The company has a healthy dividend yield of 3.2%, which can provide a steady income stream for investors.

Cons of Medtronic

  • The company has a relatively high dividend payout ratio of 78.45%, which may raise concerns about sustainability if earnings do not continue to grow.
  • Recent analyst price targets have been adjusted downward, with some analysts reducing their expectations for the stock's future performance.
  • Medtronic plc operates in a highly competitive medical technology market, which could impact its market share and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$115.01 billion
P/E Ratio
24.68
Consensus Rating
Moderate Buy
Consensus Price Target
$98.19 (+9.9% Upside)
Volume
5.46 million shares
Average Volume
6.87 million shares
Today's Range
$88.96
$90.00
50-Day Range
$82.39
$92.91
52-Week Range
$79.29
$96.25
Dividend Yield
3.17%
Vertex Pharmaceuticals stock logo

20. Vertex Pharmaceuticals NASDAQ:VRTX

$385.65 +10.67 (+2.85%)
Closing price 08/6/2025 04:00 PM Eastern
Extended Trading
$384.78 -0.86 (-0.22%)
As of 08/6/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • The current stock price is around $462, which reflects a strong market position and potential for growth in the biotechnology sector.
  • Vertex Pharmaceuticals has a solid reputation in developing therapies for cystic fibrosis, a critical area of healthcare with ongoing demand.
  • Recent earnings reports indicate a revenue increase compared to the previous year, suggesting resilience and potential for future profitability.

Cons of Vertex Pharmaceuticals

  • The company recently missed earnings expectations, which may raise concerns about its short-term financial performance.
  • Analysts have issued several downgrades, indicating a shift in sentiment that could affect stock performance negatively.
  • Vertex Pharmaceuticals has a negative net margin, which suggests that the company is currently not profitable, raising concerns about its operational efficiency.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$96.29 billion
P/E Ratio
27.57
Consensus Rating
Moderate Buy
Consensus Price Target
$497.10 (+28.9% Upside)
Volume
4.73 million shares
Average Volume
1.65 million shares
Today's Range
$372.35
$390.56
50-Day Range
$374.98
$479.53
52-Week Range
$372.35
$519.88
Dividend Yield
N/A
Bristol Myers Squibb stock logo

21. Bristol Myers Squibb NYSE:BMY

$44.82 -1.03 (-2.24%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$44.98 +0.16 (+0.36%)
As of 08/6/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol Myers Squibb

Pros of Bristol Myers Squibb

  • The current stock price is around $45, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • Bristol-Myers Squibb has a strong portfolio of products, including recent advancements in treatments for various cancers and autoimmune diseases, which can drive future revenue growth.
  • The company reported earnings per share (EPS) of $1.46, exceeding expectations, indicating strong financial performance and potential for continued profitability.

Cons of Bristol Myers Squibb

  • The company has a relatively high debt-to-equity ratio, which may indicate financial risk and could affect its ability to invest in new projects or weather economic downturns.
  • Recent trading volumes have shown fluctuations, which could suggest volatility in the stock price and potential uncertainty among investors.
  • Despite recent revenue growth, the company faces significant competition in the biopharmaceutical market, which could impact its market share and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$93.32 billion
P/E Ratio
18.07
Consensus Rating
Hold
Consensus Price Target
$56.38 (+25.8% Upside)
Volume
11.31 million shares
Average Volume
13.93 million shares
Today's Range
$44.74
$45.91
50-Day Range
$43.37
$50.68
52-Week Range
$42.96
$63.33
Dividend Yield
5.41%
McKesson stock logo

22. McKesson NYSE:MCK

$704.85 -4.64 (-0.65%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$691.00 -13.85 (-1.96%)
As of 08/6/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • The current stock price is around $720, reflecting a strong performance within the healthcare sector.
  • McKesson Co. recently reported a significant year-over-year revenue increase of nearly 19%, indicating robust growth potential.
  • The company has a solid market capitalization of approximately $88.72 billion, showcasing its stability and presence in the market.

Cons of McKesson

  • The company has a negative return on equity of over 201%, which may raise concerns about its profitability and efficiency in generating returns for shareholders.
  • Despite revenue growth, McKesson Co. reported a net margin of only 0.92%, indicating that profit generation is relatively low compared to its sales.
  • The stock has shown volatility with a beta of 0.50, suggesting that it may not respond strongly to market movements, which could limit potential gains.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$88.77 billion
P/E Ratio
27.29
Consensus Rating
Moderate Buy
Consensus Price Target
$710.17 (+0.8% Upside)
Volume
1.27 million shares
Average Volume
624,894 shares
Today's Range
$687.20
$711.48
50-Day Range
$693.57
$735.41
52-Week Range
$464.42
$737.89
Dividend Yield
0.40%
HCA Healthcare stock logo

23. HCA Healthcare NYSE:HCA

$366.08 +2.27 (+0.62%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$364.50 -1.58 (-0.43%)
As of 08/6/2025 05:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • The current stock price is around $366, reflecting a recent increase, which may indicate positive market sentiment towards the company.
  • HCA Healthcare, Inc. reported earnings per share of $6.84 for the latest quarter, exceeding analysts' expectations, which suggests strong financial performance.
  • The company has shown a year-over-year revenue growth of 6.4%, indicating a solid upward trend in its business operations.

Cons of HCA Healthcare

  • The company has a notably high negative return on equity of over 7,363%, which may raise concerns about its profitability and financial health.
  • HCA Healthcare, Inc. has a debt-to-equity ratio of 69.07, indicating a high level of debt compared to equity, which could pose risks in times of economic downturn.
  • Recent analyst downgrades, including a shift from "outperform" to "peer perform," may signal a lack of confidence in the stock's near-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$85.13 billion
P/E Ratio
15.39
Consensus Rating
Moderate Buy
Consensus Price Target
$395.69 (+8.1% Upside)
Volume
1.13 million shares
Average Volume
1.61 million shares
Today's Range
$363.99
$370.13
50-Day Range
$334.26
$389.81
52-Week Range
$289.98
$417.14
Dividend Yield
0.79%
CVS Health stock logo

24. CVS Health NYSE:CVS

$63.55 +0.13 (+0.20%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$63.28 -0.26 (-0.41%)
As of 08/6/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • CVS Health Co. reported strong earnings, with earnings per share of $1.81, significantly exceeding analysts' expectations, indicating robust financial performance.
  • The company has shown a year-over-year revenue increase of 8.4%, reflecting its growth potential and ability to expand its market presence.
  • CVS Health Co. recently declared a quarterly dividend of $0.665, which translates to an annualized dividend yield of 4.3%, providing a steady income stream for investors.

Cons of CVS Health

  • The company experienced a slight decline in earnings per share compared to the same quarter last year, which may raise concerns about its profitability trajectory.
  • CVS Health Co. has a relatively high dividend payout ratio of 74.30%, which could limit its ability to reinvest in growth opportunities.
  • Recent insider trading activity shows that some directors are selling shares, which could signal a lack of confidence in the company's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$80.44 billion
P/E Ratio
17.75
Consensus Rating
Moderate Buy
Consensus Price Target
$75.39 (+18.6% Upside)
Volume
5.29 million shares
Average Volume
9.39 million shares
Today's Range
$62.52
$63.90
50-Day Range
$58.82
$69.56
52-Week Range
$43.56
$72.51
Dividend Yield
4.19%
GSK stock logo

25. GSK NYSE:GSK

$36.78 -0.54 (-1.43%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$36.77 -0.01 (-0.03%)
As of 08/6/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • The current stock price is around $38, which is relatively stable compared to its 52-week high of $44.67, indicating potential for recovery and growth.
  • GSK plc recently reported earnings that exceeded analysts' expectations, showcasing strong financial performance with a revenue increase compared to the previous year.
  • The company has a solid dividend yield of approximately 4.43%, providing a steady income stream for investors.

Cons of GSK

  • Analysts have issued a "strong sell" rating, indicating concerns about the stock's future performance and potential risks.
  • The company's debt-to-equity ratio is relatively high, which may raise concerns about financial leverage and risk management.
  • Despite recent earnings growth, the net margin remains modest, suggesting that profitability could be a concern in the long term.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$76.14 billion
P/E Ratio
17.03
Consensus Rating
Reduce
Consensus Price Target
$37.38 (+1.6% Upside)
Volume
3.12 million shares
Average Volume
6.18 million shares
Today's Range
$36.75
$37.38
50-Day Range
$36.21
$42.50
52-Week Range
$31.72
$44.67
Dividend Yield
4.54%
Cigna Group stock logo

26. Cigna Group NYSE:CI

$270.05 -0.69 (-0.26%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$270.22 +0.17 (+0.06%)
As of 08/6/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about Cigna Group

Pros of Cigna Group

  • The current stock price is around $271, which may present a buying opportunity for investors looking for value in the health services sector.
  • The Cigna Group reported strong quarterly earnings, with an EPS of $7.20, exceeding analysts' expectations, indicating robust financial performance.
  • The company has a solid revenue growth of 11.0% compared to the same quarter last year, showcasing its ability to expand and capture market share.

Cons of Cigna Group

  • Despite recent earnings growth, the company's net margin is relatively low at 1.92%, which may raise concerns about profitability in a competitive market.
  • The stock has experienced volatility, with a 12-month high of $370.83 and a low of $256.89, indicating potential risks for investors regarding price fluctuations.
  • Analysts have mixed ratings, with some downgrading the stock from "buy" to "hold," suggesting uncertainty about future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$72.27 billion
P/E Ratio
14.74
Consensus Rating
Buy
Consensus Price Target
$377.72 (+39.9% Upside)
Volume
2.15 million shares
Average Volume
1.94 million shares
Today's Range
$266.29
$274.60
50-Day Range
$262.26
$334.71
52-Week Range
$256.89
$370.83
Dividend Yield
2.23%
Zoetis stock logo

27. Zoetis NYSE:ZTS

$146.63 +0.51 (+0.35%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$145.40 -1.23 (-0.84%)
As of 08/6/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. More about Zoetis

Pros of Zoetis

  • The current stock price is around $147.40, which reflects a stable market position and potential for growth.
  • Zoetis Inc. reported a strong quarterly earnings performance, with earnings per share exceeding analysts' expectations, indicating robust financial health.
  • The company has a high net margin, showcasing its efficiency in converting revenue into profit, which is attractive for investors seeking profitability.

Cons of Zoetis

  • Recent target price reductions by analysts, including a downgrade to a "neutral" rating, may indicate concerns about future performance.
  • The stock has experienced fluctuations, with a 1-year high of $200.33 and a low of $139.70, suggesting volatility that could deter risk-averse investors.
  • Insider selling activity, such as the recent sale of shares by an executive vice president, may raise questions about the company's future outlook from those within the organization.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$65.05 billion
P/E Ratio
25.24
Consensus Rating
Moderate Buy
Consensus Price Target
$204.63 (+39.6% Upside)
Volume
4.99 million shares
Average Volume
3.70 million shares
Today's Range
$144.25
$147.30
50-Day Range
$145.76
$170.40
52-Week Range
$139.70
$200.33
Dividend Yield
1.37%
Elevance Health stock logo

28. Elevance Health NYSE:ELV

$276.39 -0.02 (-0.01%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$278.25 +1.86 (+0.67%)
As of 08/6/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$62.24 billion
P/E Ratio
11.76
Consensus Rating
Moderate Buy
Consensus Price Target
$418.19 (+51.3% Upside)
Volume
2.49 million shares
Average Volume
3.27 million shares
Today's Range
$273.71
$280.80
50-Day Range
$274.10
$395.76
52-Week Range
$273.71
$567.26
Dividend Yield
2.49%
Regeneron Pharmaceuticals stock logo

29. Regeneron Pharmaceuticals NASDAQ:REGN

$555.13 -14.77 (-2.59%)
Closing price 08/6/2025 04:00 PM Eastern
Extended Trading
$555.15 +0.02 (+0.00%)
As of 08/6/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • The current stock price is around $568, which may present a buying opportunity for investors looking for growth in the biopharmaceutical sector.
  • Regeneron Pharmaceuticals, Inc. has a strong market capitalization of over $60 billion, indicating a solid position in the industry and potential for stability.
  • The company recently reported impressive quarterly earnings, exceeding analysts' expectations significantly, which reflects strong operational performance.

Cons of Regeneron Pharmaceuticals

  • Recent analyst reports have shown a range of price targets, with some analysts lowering their expectations, which may indicate uncertainty about future performance.
  • Despite strong earnings, the stock has experienced volatility, which could pose risks for investors looking for stable returns.
  • With a P/E ratio that may be considered high compared to industry averages, some investors might view the stock as overvalued.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$61.53 billion
P/E Ratio
13.99
Consensus Rating
Moderate Buy
Consensus Price Target
$832.73 (+50.0% Upside)
Volume
864,754 shares
Average Volume
969,242 shares
Today's Range
$550.50
$573.47
50-Day Range
$483.07
$605.39
52-Week Range
$476.49
$1,211.20
Dividend Yield
0.62%
Cencora stock logo

30. Cencora NYSE:COR

$283.90 -8.45 (-2.89%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$284.49 +0.59 (+0.21%)
As of 08/6/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • The current stock price is around $292, which reflects a strong market position and investor confidence in the company's growth potential.
  • Recent analyst upgrades have increased price targets significantly, indicating positive sentiment and potential for future price appreciation.
  • Institutional ownership is high, with over 97% of the stock held by institutional investors and hedge funds, suggesting strong backing and confidence in the company's performance.

Cons of Cencora

  • Insider selling has been observed, with significant shares sold recently, which may raise concerns about the executives' confidence in the company's future performance.
  • The stock has experienced fluctuations, with recent trading volumes indicating volatility, which can be a risk for investors looking for stable returns.
  • The P/E ratio is relatively high at 33.91, suggesting that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$56.66 billion
P/E Ratio
32.94
Consensus Rating
Moderate Buy
Consensus Price Target
$309.83 (+9.1% Upside)
Volume
2.38 million shares
Average Volume
985,320 shares
Today's Range
$273.43
$287.27
50-Day Range
$283.90
$302.43
52-Week Range
$218.65
$309.35
Dividend Yield
0.75%
Alnylam Pharmaceuticals stock logo

31. Alnylam Pharmaceuticals NASDAQ:ALNY

$428.14 +9.23 (+2.20%)
Closing price 08/6/2025 04:00 PM Eastern
Extended Trading
$428.09 -0.05 (-0.01%)
As of 08/6/2025 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More about Alnylam Pharmaceuticals

Pros of Alnylam Pharmaceuticals

  • The current stock price is around $420.60, reflecting a recent increase, which may indicate positive market sentiment towards the company's growth potential.
  • Alnylam Pharmaceuticals, Inc. reported a significant earnings surprise, with earnings per share of $0.32, surpassing analysts' expectations by a substantial margin, which could signal strong operational performance.
  • The company has shown a year-over-year revenue growth of 17.3%, suggesting a robust demand for its products and a solid business model.

Cons of Alnylam Pharmaceuticals

  • The company has a high debt-to-equity ratio of 8.88, which may indicate a reliance on debt financing that could pose risks if market conditions change.
  • Alnylam Pharmaceuticals, Inc. has a negative return on equity of 444.38%, suggesting that the company is not currently generating profit relative to shareholder equity, which could deter potential investors.
  • Despite recent revenue growth, the company has a negative net margin of 12.96%, indicating that it is currently operating at a loss, which could raise concerns about its profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$54.91 billion
P/E Ratio
-173.34
Consensus Rating
Moderate Buy
Consensus Price Target
$401.12 (-6.3% Downside)
Volume
1.18 million shares
Average Volume
1.17 million shares
Today's Range
$415.00
$428.69
50-Day Range
$292.90
$428.14
52-Week Range
$205.87
$428.69
Dividend Yield
N/A
IDEXX Laboratories stock logo

32. IDEXX Laboratories NASDAQ:IDXX

$624.19 -17.75 (-2.77%)
Closing price 08/6/2025 04:00 PM Eastern
Extended Trading
$622.50 -1.69 (-0.27%)
As of 08/6/2025 06:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • IDEXX Laboratories, Inc. has received multiple upgrades from analysts, with recent ratings indicating a strong buy sentiment, suggesting confidence in the company's future performance.
  • The current stock price is around $641.94, reflecting a significant increase from its 12-month low, indicating positive market sentiment and potential for further growth.
  • Institutional ownership is high, with approximately 87.84% of the stock held by hedge funds and other institutional investors, which often signals confidence in the company's stability and growth prospects.

Cons of IDEXX Laboratories

  • The stock has experienced volatility, with a recent trading down of about $40.84, which may indicate market uncertainty and potential risks for investors.
  • Insider selling activity has been noted, with a director selling a significant portion of their shares, which could raise concerns about the company's future outlook from those within the organization.
  • The company's high P/E ratio suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$51.63 billion
P/E Ratio
51.97
Consensus Rating
Moderate Buy
Consensus Price Target
$623.56 (-0.1% Downside)
Volume
816,294 shares
Average Volume
770,026 shares
Today's Range
$623.40
$647.25
50-Day Range
$512.52
$682.78
52-Week Range
$356.14
$688.12
Dividend Yield
N/A
Becton, Dickinson and Company stock logo

33. Becton, Dickinson and Company NYSE:BDX

$172.50 -4.39 (-2.48%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$173.14 +0.64 (+0.37%)
As of 08/6/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • The company recently reported earnings per share that exceeded expectations, indicating strong financial performance and effective management.
  • Becton, Dickinson and Company has shown a year-over-year revenue increase, suggesting growth potential in its market segment.
  • The current stock price is around $175, which may present a buying opportunity for investors looking for value in the medical instruments sector.

Cons of Becton, Dickinson and Company

  • Recent downgrades from multiple analysts indicate a shift in market sentiment, which could lead to decreased investor confidence.
  • The company's revenue for the latest quarter fell short of consensus estimates, raising concerns about future growth prospects.
  • Insider selling activity has been noted, which may signal a lack of confidence from executives regarding the company's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$50.70 billion
P/E Ratio
32.92
Consensus Rating
Hold
Consensus Price Target
$212.88 (+23.4% Upside)
Volume
4.22 million shares
Average Volume
3.07 million shares
Today's Range
$172.20
$177.39
50-Day Range
$168.54
$185.52
52-Week Range
$163.33
$251.99
Dividend Yield
2.35%
Edwards Lifesciences stock logo

34. Edwards Lifesciences NYSE:EW

$78.56 -0.68 (-0.86%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$79.32 +0.76 (+0.96%)
As of 08/6/2025 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More about Edwards Lifesciences

Pros of Edwards Lifesciences

  • The current stock price is around $79.30, which is near the average price target of $85.71 set by analysts, indicating potential for growth.
  • Recent upgrades from multiple analysts, including a boost in price targets, suggest strong confidence in the company's future performance.
  • Edwards Lifesciences Co. has a solid market capitalization of approximately $46.52 billion, reflecting its stability and growth potential in the medical research sector.

Cons of Edwards Lifesciences

  • Despite recent upgrades, one analyst has rated the stock with a sell rating, indicating some skepticism about its short-term performance.
  • Insider sales have occurred, with significant shares sold by executives, which could signal a lack of confidence in the stock's immediate future.
  • The stock has experienced fluctuations, with a 12-month low of $59.41, suggesting volatility that may concern risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$46.48 billion
P/E Ratio
11.30
Consensus Rating
Moderate Buy
Consensus Price Target
$85.71 (+9.1% Upside)
Volume
3.96 million shares
Average Volume
5.17 million shares
Today's Range
$77.64
$79.63
50-Day Range
$73.31
$81.15
52-Week Range
$60.88
$83.00
Dividend Yield
N/A
Veeva Systems stock logo

35. Veeva Systems NYSE:VEEV

$282.25 +0.79 (+0.28%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$281.50 -0.75 (-0.27%)
As of 08/6/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. More about Veeva Systems

Pros of Veeva Systems

  • The current stock price is around $283.00, which may present a buying opportunity for investors looking for growth in the life sciences software sector.
  • Veeva Systems Inc. offers a comprehensive suite of cloud-based software solutions tailored for the life sciences industry, including the latest Veeva Commercial Cloud and Veeva Vault, which enhance operational efficiency for pharmaceutical companies.
  • Insider ownership stands at 10.30%, indicating that company executives have a significant stake in the business, which can align their interests with those of shareholders.

Cons of Veeva Systems

  • Recent insider sales, totaling 1,378 shares valued at approximately $394,217, may raise concerns about the company's short-term outlook from those who are privy to internal information.
  • The stock has experienced fluctuations, with a noted decrease in insider positions, which could indicate potential volatility in the stock price.
  • As the market for cloud-based solutions becomes increasingly competitive, Veeva Systems Inc. may face challenges in maintaining its market share against emerging players.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$45.99 billion
P/E Ratio
59.80
Consensus Rating
Moderate Buy
Consensus Price Target
$274.17 (-2.9% Downside)
Volume
778,546 shares
Average Volume
1.24 million shares
Today's Range
$278.36
$282.93
50-Day Range
$275.82
$292.77
52-Week Range
$182.21
$296.72
Dividend Yield
N/A
Takeda Pharmaceutical stock logo

36. Takeda Pharmaceutical NYSE:TAK

$14.30 +0.10 (+0.67%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$14.28 -0.02 (-0.14%)
As of 08/6/2025 04:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • The current stock price is approximately $14.67, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • Takeda Pharmaceutical Company Limited has recently experienced a significant increase in trading volume, indicating heightened investor interest and potential momentum.
  • The company reported a market capitalization of around $46.68 billion, suggesting a strong position in the market and potential for growth.

Cons of Takeda Pharmaceutical

  • The company recently reported earnings per share (EPS) of $0.16, which missed the consensus estimate, indicating potential challenges in meeting financial expectations.
  • Takeda Pharmaceutical Company Limited's revenue for the last quarter was below analyst estimates, which may raise concerns about its growth trajectory.
  • The stock has shown volatility, with fluctuations in trading volume and price, which could pose risks for investors seeking stability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$45.18 billion
P/E Ratio
47.65
Consensus Rating
Buy
Consensus Price Target
N/A
Volume
5.46 million shares
Average Volume
5.40 million shares
Today's Range
$14.21
$14.32
50-Day Range
$13.60
$15.55
52-Week Range
$12.80
$15.53
Dividend Yield
3.89%
Alcon stock logo

37. Alcon NYSE:ALC

$84.12 -1.43 (-1.67%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$84.12 0.00 (0.00%)
As of 08/6/2025 04:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alcon Inc researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. More about Alcon

Pros of Alcon

  • The current stock price is around $91.50, reflecting a strong performance in the market.
  • Alcon Inc. has shown a positive fifty-two week performance, indicating a growth trend that may attract investors.
  • Institutional ownership is significant, with a high percentage indicating confidence from large investors.

Cons of Alcon

  • Despite recent positive trends, the average daily volume has decreased, which may indicate reduced trading interest.
  • The month-to-month change in shares shorted has shown a significant decline, which could suggest volatility in investor confidence.
  • With a relatively high number of shares outstanding, the stock may face pressure from dilution if new shares are issued.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$42.19 billion
P/E Ratio
37.38
Consensus Rating
Moderate Buy
Consensus Price Target
$106.13 (+26.2% Upside)
Volume
2.15 million shares
Average Volume
1.54 million shares
Today's Range
$83.60
$85.31
50-Day Range
$84.12
$92.25
52-Week Range
$80.48
$101.10
Dividend Yield
N/A
ResMed stock logo

38. ResMed NYSE:RMD

$280.25 -4.75 (-1.67%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$280.82 +0.57 (+0.20%)
As of 08/6/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. More about ResMed

Pros of ResMed

  • The current stock price is around $300, reflecting strong market interest and potential for growth.
  • Recent upgrades from multiple research firms indicate positive sentiment, with price targets raised significantly, suggesting confidence in the company's future performance.
  • Institutional investors and hedge funds own nearly 55% of the company's stock, indicating strong backing and confidence from major financial players.

Cons of ResMed

  • Insider selling of over 29,000 shares recently may raise concerns about the confidence of those closest to the company.
  • Despite positive ratings, one analyst has issued a sell rating, indicating potential risks that some investors may want to consider.
  • The competitive landscape in the medical device industry is intense, which could impact ResMed Inc.'s market share and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$41.79 billion
P/E Ratio
29.47
Consensus Rating
Moderate Buy
Consensus Price Target
$274.83 (-1.9% Downside)
Volume
985,888 shares
Average Volume
1.13 million shares
Today's Range
$279.45
$285.49
50-Day Range
$243.90
$291.30
52-Week Range
$199.92
$293.08
Dividend Yield
0.74%
Haleon stock logo

39. Haleon NYSE:HLN

$9.28 -0.02 (-0.16%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$9.30 +0.02 (+0.22%)
As of 08/6/2025 06:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More about Haleon

Pros of Haleon

  • Recent upgrades from major financial institutions, including Morgan Stanley and BNP Paribas, indicate strong confidence in Haleon plc's growth potential, with price targets set at $11.25 and $13.40 respectively.
  • The current stock price is around $9.65, which may present a buying opportunity for investors looking for undervalued stocks in the consumer healthcare sector.
  • Haleon plc has a solid market capitalization of approximately $43.35 billion, suggesting a stable financial foundation and the ability to invest in growth initiatives.

Cons of Haleon

  • Despite recent upgrades, the stock has experienced a decline of about 1.6%, which may raise concerns about short-term performance and market sentiment.
  • The company has a relatively high P/E ratio of 24.74, which could indicate that the stock is overvalued compared to its earnings, potentially deterring value-focused investors.
  • Haleon plc's debt-to-equity ratio of 0.53 suggests a moderate level of debt, which could pose risks if the company faces financial challenges or rising interest rates.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$41.73 billion
P/E Ratio
23.78
Consensus Rating
Moderate Buy
Consensus Price Target
$12.33 (+32.9% Upside)
Volume
6.89 million shares
Average Volume
11.97 million shares
Today's Range
$9.23
$9.30
50-Day Range
$9.28
$11.42
52-Week Range
$8.86
$11.42
Dividend Yield
2.68%
argenex stock logo

40. argenex NASDAQ:ARGX

$673.15 -1.75 (-0.26%)
Closing price 08/6/2025 04:00 PM Eastern
Extended Trading
$673.42 +0.27 (+0.04%)
As of 08/6/2025 06:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenex

Pros of argenex

  • The company reported strong earnings per share of $3.74, significantly exceeding analyst expectations, indicating robust financial performance.
  • With a net margin of approximately 41%, argenx SE demonstrates effective cost management and profitability, which can be attractive to investors.
  • Recent analyst upgrades have increased the target price for argenx SE, with several firms setting targets above $700, suggesting positive market sentiment.

Cons of argenex

  • Despite strong earnings, the stock's high valuation may pose risks if future performance does not meet elevated expectations set by analysts.
  • Market volatility can impact stock prices, and any negative news regarding the biotechnology sector could adversely affect argenx SE's stock performance.
  • Competition in the biotechnology field is intense, and new entrants or advancements by competitors could threaten argenx SE's market position.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$41.30 billion
P/E Ratio
34.52
Consensus Rating
Buy
Consensus Price Target
$746.81 (+10.9% Upside)
Volume
410,774 shares
Average Volume
445,980 shares
Today's Range
$668.64
$680.12
50-Day Range
$537.92
$690.32
52-Week Range
$496.91
$696.21
Dividend Yield
N/A
Cardinal Health stock logo

41. Cardinal Health NYSE:CAH

$156.78 -1.46 (-0.92%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$157.50 +0.72 (+0.46%)
As of 08/6/2025 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • Recent upgrades from multiple analysts, including a target price increase to $170.00, indicate strong market confidence in Cardinal Health, Inc.'s growth potential.
  • The current stock price is around $155.97, which is near its 1-year high of $168.44, suggesting a positive trend in investor sentiment.
  • Cardinal Health, Inc. reported earnings per share of $2.35, exceeding analysts' expectations, which reflects strong operational performance.

Cons of Cardinal Health

  • The company has a negative return on equity of 68.84%, which may raise concerns about its profitability and efficiency in generating returns for shareholders.
  • Despite a revenue of $54.88 billion, it fell short of analysts' expectations, indicating potential challenges in meeting market demands.
  • Cardinal Health, Inc. has a relatively low net margin of 0.70%, suggesting that it may face difficulties in maintaining profitability amidst rising costs.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$37.77 billion
P/E Ratio
24.46
Consensus Rating
Moderate Buy
Consensus Price Target
$158.07 (+0.8% Upside)
Volume
1.71 million shares
Average Volume
1.71 million shares
Today's Range
$153.81
$158.17
50-Day Range
$153.07
$167.92
52-Week Range
$96.05
$168.44
Dividend Yield
1.29%
BeOne Medicines stock logo

42. BeOne Medicines NASDAQ:ONC

$298.52 -8.71 (-2.84%)
As of 08/6/2025 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Market Capitalization
$33.67 billion
P/E Ratio
-80.25
Consensus Rating
Buy
Consensus Price Target
$327.56 (+9.7% Upside)
Volume
529,316 shares
Average Volume
444,232 shares
Today's Range
$287.00
$313.29
50-Day Range
$240.41
$307.23
52-Week Range
$170.36
$313.29
Dividend Yield
N/A
Agilent Technologies stock logo

43. Agilent Technologies NYSE:A

$113.32 -1.57 (-1.37%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$113.96 +0.64 (+0.56%)
As of 08/6/2025 07:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • The company recently reported earnings per share of $1.31, exceeding expectations, which indicates strong financial performance and potential for growth.
  • Agilent Technologies, Inc. has shown a year-over-year revenue increase of 6.0%, suggesting a positive trend in sales and market demand.
  • The current stock price is around $117, reflecting a stable valuation in the market, which may attract investors looking for solid investment opportunities.

Cons of Agilent Technologies

  • Analysts have mixed ratings on the stock, with some reducing their price targets, indicating uncertainty about future performance.
  • The dividend payout ratio is 24.44%, which, while sustainable, may limit the company's ability to reinvest profits into growth opportunities.
  • Recent insider selling by the CEO could signal a lack of confidence in the stock's short-term performance, which may concern potential investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$32.64 billion
P/E Ratio
27.98
Consensus Rating
Moderate Buy
Consensus Price Target
$139.77 (+23.3% Upside)
Volume
1.06 million shares
Average Volume
1.84 million shares
Today's Range
$112.56
$115.08
50-Day Range
$110.92
$124.18
52-Week Range
$96.43
$153.84
Dividend Yield
0.86%
GE HealthCare Technologies stock logo

44. GE HealthCare Technologies NASDAQ:GEHC

$69.96 -0.78 (-1.10%)
Closing price 08/6/2025 04:00 PM Eastern
Extended Trading
$69.90 -0.05 (-0.08%)
As of 08/6/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. More about GE HealthCare Technologies

Pros of GE HealthCare Technologies

  • The company recently reported earnings per share of $1.06, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
  • GE HealthCare Technologies Inc. has a solid return on equity of 23.93%, suggesting effective management and profitability relative to shareholder equity.
  • The current stock price is around $73.59, which may present a buying opportunity for investors looking for value in the healthcare sector.

Cons of GE HealthCare Technologies

  • The quick ratio of 0.93 indicates that the company may have difficulty meeting its short-term liabilities, which could pose a risk in times of financial stress.
  • Despite recent revenue growth, the net margin of 11.22% suggests that profitability could be impacted by rising costs or competitive pressures in the healthcare market.
  • Some analysts have lowered their price targets for the stock, indicating a cautious outlook that could affect investor sentiment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$32.30 billion
P/E Ratio
14.34
Consensus Rating
Moderate Buy
Consensus Price Target
$88.55 (+26.6% Upside)
Volume
5.15 million shares
Average Volume
4.21 million shares
Today's Range
$69.58
$71.03
50-Day Range
$69.85
$77.74
52-Week Range
$57.65
$94.80
Dividend Yield
0.20%
IQVIA stock logo

45. IQVIA NYSE:IQV

$177.41 -6.52 (-3.54%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$172.98 -4.43 (-2.50%)
As of 08/6/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More about IQVIA

Pros of IQVIA

  • The company reported a strong earnings per share (EPS) of $2.81 for the latest quarter, surpassing analysts' expectations, which indicates robust financial performance.
  • IQVIA Holdings Inc. achieved a revenue of $4.02 billion during the quarter, reflecting a year-over-year growth of 5.3%, showcasing its ability to expand in the market.
  • The current stock price is around $182, which may present a buying opportunity for investors looking for growth in the healthcare analytics sector.

Cons of IQVIA

  • The stock has experienced fluctuations, with a fifty-two week high of $252.88 and a low of $134.65, indicating potential volatility that could concern risk-averse investors.
  • Insider trading activity shows a decrease in ownership by insiders, which may raise questions about their confidence in the company's future performance.
  • The company has a relatively high debt-to-equity ratio of 2.45, suggesting that it relies heavily on debt financing, which could pose risks in a rising interest rate environment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$31.27 billion
P/E Ratio
25.67
Consensus Rating
Moderate Buy
Consensus Price Target
$228.62 (+28.9% Upside)
Volume
1.66 million shares
Average Volume
2.41 million shares
Today's Range
$176.47
$183.79
50-Day Range
$138.59
$201.06
52-Week Range
$134.65
$252.88
Dividend Yield
N/A
Humana stock logo

46. Humana NYSE:HUM

$257.04 +2.57 (+1.01%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$256.26 -0.77 (-0.30%)
As of 08/6/2025 07:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • The current stock price is around $251.55, which may present a buying opportunity for investors looking for value in the healthcare sector.
  • Humana Inc. reported a revenue increase of 9.6% year-over-year, indicating strong growth potential and demand for its medical and specialty insurance products.
  • The company has a solid market capitalization of approximately $30.36 billion, reflecting its stability and presence in the insurance market.

Cons of Humana

  • The company recently missed analysts' earnings estimates, reporting $6.27 EPS compared to the expected $6.32, which may raise concerns about its profitability.
  • Several analysts have lowered their price targets for Humana Inc., with some setting targets as low as $260.00, indicating a cautious outlook.
  • Humana Inc. has a relatively high price-to-earnings (P/E) ratio of around 17.80, which could suggest that the stock is overvalued compared to its earnings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$30.61 billion
P/E Ratio
19.73
Consensus Rating
Hold
Consensus Price Target
$281.62 (+9.6% Upside)
Volume
1.26 million shares
Average Volume
1.99 million shares
Today's Range
$252.43
$259.46
50-Day Range
$220.08
$264.97
52-Week Range
$206.87
$382.72
Dividend Yield
1.43%
DexCom stock logo

47. DexCom NASDAQ:DXCM

$76.40 +0.94 (+1.25%)
Closing price 08/6/2025 04:00 PM Eastern
Extended Trading
$76.17 -0.23 (-0.30%)
As of 08/6/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. More about DexCom

Pros of DexCom

  • The current stock price is around $88, reflecting a strong market position in the medical device sector, particularly in continuous glucose monitoring systems.
  • Recent institutional investments indicate growing confidence in DexCom, Inc., with several hedge funds increasing their holdings significantly, suggesting potential for future growth.
  • DexCom, Inc. specializes in innovative medical technology, focusing on continuous glucose monitoring systems, which are essential for diabetes management, a growing health concern globally.

Cons of DexCom

  • Insider selling has occurred recently, with a total of 28,656 shares sold, which may raise concerns about the executives' confidence in the company's short-term performance.
  • The executive vice president's recent sale of shares, resulting in a decrease in their position, could signal potential issues or a lack of confidence in the company's immediate future.
  • Despite the strong institutional backing, the low insider ownership percentage might indicate a lack of alignment between management and shareholder interests.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$29.59 billion
P/E Ratio
53.06
Consensus Rating
Moderate Buy
Consensus Price Target
$99.89 (+30.8% Upside)
Volume
4.83 million shares
Average Volume
3.53 million shares
Today's Range
$74.80
$77.95
50-Day Range
$75.46
$89.53
52-Week Range
$57.52
$93.25
Dividend Yield
N/A
BioNTech stock logo

48. BioNTech NASDAQ:BNTX

$111.30 +0.23 (+0.21%)
Closing price 08/6/2025 04:00 PM Eastern
Extended Trading
$110.09 -1.21 (-1.09%)
As of 08/6/2025 06:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. More about BioNTech

Pros of BioNTech

  • The current stock price is around $112.89, which may present a buying opportunity for investors looking for growth in the biotechnology sector.
  • Recent coverage by analysts has resulted in multiple buy ratings, indicating strong market confidence in BioNTech SE's future performance.
  • BioNTech SE has a robust market capitalization of approximately $27.14 billion, suggesting a solid financial foundation and potential for further growth.

Cons of BioNTech

  • The company has a negative price-to-earnings (PE) ratio, which may indicate challenges in profitability and could deter risk-averse investors.
  • Despite recent positive ratings, the stock has shown volatility, with a beta of 1.29, suggesting it may be more susceptible to market fluctuations.
  • BioNTech SE's stock has a wide range in its 52-week performance, with a low of $76.53 and a high of $131.49, indicating potential instability in its market value.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$26.70 billion
P/E Ratio
-69.56
Consensus Rating
Moderate Buy
Consensus Price Target
$135.91 (+22.1% Upside)
Volume
1.18 million shares
Average Volume
660,929 shares
Today's Range
$108.90
$111.43
50-Day Range
$95.71
$115.64
52-Week Range
$78.39
$131.49
Dividend Yield
N/A
Mettler-Toledo International stock logo

49. Mettler-Toledo International NYSE:MTD

$1,220.96 -22.98 (-1.85%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$1,221.05 +0.09 (+0.01%)
As of 08/6/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mettler-Toledo International Inc manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. More about Mettler-Toledo International

Pros of Mettler-Toledo International

  • The company reported earnings per share of $10.09 for the latest quarter, surpassing analysts' expectations, indicating strong financial performance.
  • Recent revenue growth of 3.9% year-over-year suggests that Mettler-Toledo International Inc. is expanding its market presence and demand for its precision instruments.
  • The current stock price is around $1,159.93, reflecting a robust valuation in the precision instruments sector.

Cons of Mettler-Toledo International

  • The director's recent sale of 1,062 shares, representing an 89.85% decrease in their ownership, may raise concerns about insider confidence in the company's future performance.
  • Despite positive earnings, the company has a negative return on equity of 476.07%, which could indicate inefficiencies in generating profit from shareholders' equity.
  • Corporate insiders own only 0.77% of the company's stock, suggesting limited alignment between management and shareholder interests.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$25.62 billion
P/E Ratio
30.92
Consensus Rating
Moderate Buy
Consensus Price Target
$1,288.89 (+5.6% Upside)
Volume
184,758 shares
Average Volume
172,926 shares
Today's Range
$1,206.67
$1,251.54
50-Day Range
$1,138.44
$1,266.11
52-Week Range
$946.69
$1,521.01
Dividend Yield
N/A
Koninklijke Philips stock logo

50. Koninklijke Philips NYSE:PHG

$26.20 -0.17 (-0.63%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$26.22 +0.02 (+0.06%)
As of 08/6/2025 04:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. More about Koninklijke Philips

Pros of Koninklijke Philips

  • The current stock price is around $26.46, which reflects a recent upward trend, indicating potential for growth.
  • Recent quarterly earnings exceeded expectations, with earnings per share reported at $0.41, surpassing the consensus estimate, showcasing strong financial performance.
  • Institutional investors hold a significant portion of the stock, with 13.67% ownership, suggesting confidence in the company's future prospects.

Cons of Koninklijke Philips

  • The company has a high price-to-earnings (P/E) ratio of 139.26, which may indicate that the stock is overvalued compared to its earnings, posing a risk for potential investors.
  • Despite recent revenue growth, the net margin is relatively low at 1.00%, which could raise concerns about profitability and operational efficiency.
  • Market volatility is a concern, as indicated by the stock's beta of 0.76, suggesting that the stock may not be as stable as some investors prefer.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$25.39 billion
P/E Ratio
137.92
Consensus Rating
Buy
Consensus Price Target
N/A
Volume
803,225 shares
Average Volume
1.27 million shares
Today's Range
$26.17
$26.43
50-Day Range
$22.08
$28.02
52-Week Range
$21.48
$32.91
Dividend Yield
3.12%